NEWARK, Calif., Aug. 13, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq:PTGX) today announced the appointment of
Sarah O'Dowd as an independent
director to the Protagonist Board of Directors. Ms. O'Dowd brings
broad experience in management and corporate governance to
Protagonist, including senior level oversight in the
biopharmaceutical industry. In connection with the appointment,
Chaitan Khosla, Ph.D., Professor of
Chemistry and Engineering at Stanford
University, is stepping down from his position on the
board.
"Ms. O'Dowd brings a significant amount of corporate governance,
legal and business strategy experience and expertise to the board
that will be invaluable with the continued evolution of
Protagonist," commented Dinesh V.
Patel, Ph.D., Protagonist President and Chief Executive
Officer. "She has a proven track record of driving growth-oriented
strategic plans for public companies, initially as outside
corporate counsel and more recently in executive leadership
positions. We welcome Sarah to this position as we constantly
explore opportunities to build long-term shareholder value through
our multiple clinical assets aimed at addressing significant unmet
medical needs in hematology/oncology and inflammatory bowel
diseases. In addition, we'd like to express our sincere gratitude
to Dr. Khosla for his invaluable contributions to the foundation
and progression of our research and clinical development functions
during his many years with the board and the Company."
"I am honored to be joining Protagonist board at a critical time
of its growth and expansion," commented Ms. O'Dowd. "Protagonist
has a compelling pipeline of multiple and well differentiated
assets in diverse indications, and I am looking forward to
leveraging my experience to benefit Protagonist and support the
corporate vision."
Sarah O'Dowd has been a director
of Ichor Holdings since May 2020. Ms.
O'Dowd previously served as Senior Vice President, Chief Legal
Officer and Secretary at the global technology firm Lam Research
Corporation from October 2008 to
March 2020. She also served as Lam
Research's Vice President of Human Resources from 2009 to 2012. At
Lam Research, Ms. O'Dowd led multiple initiatives relating to
shareholder outreach on governance, ethics and compliance, IP
strategy, foreign trade regulations and M&A transactions. Her
experience includes the role of Vice President and General Counsel
at FibroGen, a biopharmaceutical company, and a position on the
board of directors of Corcept Therapeutics, a pharmaceutical
company. Ms. O'Dowd currently serves on the board of directors of
the non-profit organization, the Independent Institute, and
previously served on the board of trustees of the non-profit
organization, the Reason Foundation. Ms. O'Dowd began her career at
the law firm Heller Ehrman, where she held responsibility for
business strategy. She holds a J.D. from Stanford Law School, an M.A. from Stanford University, and an A.B. from Immaculata College.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based therapeutics to address significant
unmet medical needs and transform existing treatment paradigms for
patients. The Company currently has three clinical-stage assets.
PTG-300 is an injectable hepcidin mimetic in development for the
treatment of polycythemia vera and other blood disorders. PTG-200
is an orally delivered, gut-restricted, interleukin-23 receptor
specific antagonist peptide in development for the treatment of
inflammatory bowel disease, with Crohn's disease as the initial
indication. The Company has a worldwide license and collaboration
agreement with Janssen Biotech, Inc., for the development of
PTG-200. PN-943 is an orally delivered, gut-restricted
alpha-4-beta-7 integrin specific antagonist peptide in development
for the treatment of inflammatory bowel disease, with ulcerative
colitis as the initial targeted indication.
Protagonist is headquartered in Newark, California. For further information,
please visit www.protagonist-inc.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-appoints-sarah-odowd-to-board-of-directors-301112192.html
SOURCE Protagonist Therapeutics, Inc.